Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease

Bumhee Yang, Byung Woo Jhun, Seong Mi Moon, Hyun Lee, Hye Yun Park, Kyeongman Jeon, Dae Hun Kim, Su Young Kim, SungJae Shin, Charles L. Daley, Won Jung Koh

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Patients with lung disease caused by Mycobacterium abscessus subsp. abscessus (here M. abscessus) typically have poor treatment outcomes. Although clofazimine (CFZ) has been increasingly used in the treatment of M. abscessus lung disease in clinical practice, there are no reported data on its effectiveness for this disease. This study sought to evaluate the clinical efficacy of a CFZ-containing regimen for the treatment of M. abscessus lung disease. We performed a retrospective review of the medical records of 42 patients with M. abscessus lung disease who were treated with CFZ-containing regimens between November 2013 and January 2015. CFZ was administered in combination with other antibiotics as an initial antibiotic regimen in 15 (36%) patients (initial treatment group), and it was added to an existing antibiotic regimen for refractory M. abscessus lung disease in 27 (64%) patients (salvage treatment group). Overall, there was an 81% treatment response rate based on symptoms and a 31% response rate based on radiographic findings. Conversion to culture-negative sputum samples was achieved in 10 (24%) patients after CFZ-containing antibiotic treatment, and during treatment, there were significant decreases in the positivity of semiquantitative sputum cultures for acid-fast bacilli in both the initial (P = 0.018) and salvage (P = 0.001) treatment groups. Our study suggests that CFZ-containing regimens may improve treatment outcomes in patients with M. abscessus lung disease and that a prospective evaluation of CFZ in M. abscessus lung disease is warranted.

Original languageEnglish
Article numbere02052-16
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number6
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Clofazimine
Mycobacterium
Lung Diseases
Anti-Bacterial Agents
Sputum
Therapeutics
Salvage Therapy
Bacillus
Medical Records
Acids

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Yang, B., Jhun, B. W., Moon, S. M., Lee, H., Park, H. Y., Jeon, K., ... Koh, W. J. (2017). Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy, 61(6), [e02052-16]. https://doi.org/10.1128/AAC.02052-16
Yang, Bumhee ; Jhun, Byung Woo ; Moon, Seong Mi ; Lee, Hyun ; Park, Hye Yun ; Jeon, Kyeongman ; Kim, Dae Hun ; Kim, Su Young ; Shin, SungJae ; Daley, Charles L. ; Koh, Won Jung. / Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease. In: Antimicrobial Agents and Chemotherapy. 2017 ; Vol. 61, No. 6.
@article{67905753f337477f845890dc37edbabf,
title = "Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease",
abstract = "Patients with lung disease caused by Mycobacterium abscessus subsp. abscessus (here M. abscessus) typically have poor treatment outcomes. Although clofazimine (CFZ) has been increasingly used in the treatment of M. abscessus lung disease in clinical practice, there are no reported data on its effectiveness for this disease. This study sought to evaluate the clinical efficacy of a CFZ-containing regimen for the treatment of M. abscessus lung disease. We performed a retrospective review of the medical records of 42 patients with M. abscessus lung disease who were treated with CFZ-containing regimens between November 2013 and January 2015. CFZ was administered in combination with other antibiotics as an initial antibiotic regimen in 15 (36{\%}) patients (initial treatment group), and it was added to an existing antibiotic regimen for refractory M. abscessus lung disease in 27 (64{\%}) patients (salvage treatment group). Overall, there was an 81{\%} treatment response rate based on symptoms and a 31{\%} response rate based on radiographic findings. Conversion to culture-negative sputum samples was achieved in 10 (24{\%}) patients after CFZ-containing antibiotic treatment, and during treatment, there were significant decreases in the positivity of semiquantitative sputum cultures for acid-fast bacilli in both the initial (P = 0.018) and salvage (P = 0.001) treatment groups. Our study suggests that CFZ-containing regimens may improve treatment outcomes in patients with M. abscessus lung disease and that a prospective evaluation of CFZ in M. abscessus lung disease is warranted.",
author = "Bumhee Yang and Jhun, {Byung Woo} and Moon, {Seong Mi} and Hyun Lee and Park, {Hye Yun} and Kyeongman Jeon and Kim, {Dae Hun} and Kim, {Su Young} and SungJae Shin and Daley, {Charles L.} and Koh, {Won Jung}",
year = "2017",
month = "6",
day = "1",
doi = "10.1128/AAC.02052-16",
language = "English",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

Yang, B, Jhun, BW, Moon, SM, Lee, H, Park, HY, Jeon, K, Kim, DH, Kim, SY, Shin, S, Daley, CL & Koh, WJ 2017, 'Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease', Antimicrobial Agents and Chemotherapy, vol. 61, no. 6, e02052-16. https://doi.org/10.1128/AAC.02052-16

Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease. / Yang, Bumhee; Jhun, Byung Woo; Moon, Seong Mi; Lee, Hyun; Park, Hye Yun; Jeon, Kyeongman; Kim, Dae Hun; Kim, Su Young; Shin, SungJae; Daley, Charles L.; Koh, Won Jung.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 6, e02052-16, 01.06.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease

AU - Yang, Bumhee

AU - Jhun, Byung Woo

AU - Moon, Seong Mi

AU - Lee, Hyun

AU - Park, Hye Yun

AU - Jeon, Kyeongman

AU - Kim, Dae Hun

AU - Kim, Su Young

AU - Shin, SungJae

AU - Daley, Charles L.

AU - Koh, Won Jung

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Patients with lung disease caused by Mycobacterium abscessus subsp. abscessus (here M. abscessus) typically have poor treatment outcomes. Although clofazimine (CFZ) has been increasingly used in the treatment of M. abscessus lung disease in clinical practice, there are no reported data on its effectiveness for this disease. This study sought to evaluate the clinical efficacy of a CFZ-containing regimen for the treatment of M. abscessus lung disease. We performed a retrospective review of the medical records of 42 patients with M. abscessus lung disease who were treated with CFZ-containing regimens between November 2013 and January 2015. CFZ was administered in combination with other antibiotics as an initial antibiotic regimen in 15 (36%) patients (initial treatment group), and it was added to an existing antibiotic regimen for refractory M. abscessus lung disease in 27 (64%) patients (salvage treatment group). Overall, there was an 81% treatment response rate based on symptoms and a 31% response rate based on radiographic findings. Conversion to culture-negative sputum samples was achieved in 10 (24%) patients after CFZ-containing antibiotic treatment, and during treatment, there were significant decreases in the positivity of semiquantitative sputum cultures for acid-fast bacilli in both the initial (P = 0.018) and salvage (P = 0.001) treatment groups. Our study suggests that CFZ-containing regimens may improve treatment outcomes in patients with M. abscessus lung disease and that a prospective evaluation of CFZ in M. abscessus lung disease is warranted.

AB - Patients with lung disease caused by Mycobacterium abscessus subsp. abscessus (here M. abscessus) typically have poor treatment outcomes. Although clofazimine (CFZ) has been increasingly used in the treatment of M. abscessus lung disease in clinical practice, there are no reported data on its effectiveness for this disease. This study sought to evaluate the clinical efficacy of a CFZ-containing regimen for the treatment of M. abscessus lung disease. We performed a retrospective review of the medical records of 42 patients with M. abscessus lung disease who were treated with CFZ-containing regimens between November 2013 and January 2015. CFZ was administered in combination with other antibiotics as an initial antibiotic regimen in 15 (36%) patients (initial treatment group), and it was added to an existing antibiotic regimen for refractory M. abscessus lung disease in 27 (64%) patients (salvage treatment group). Overall, there was an 81% treatment response rate based on symptoms and a 31% response rate based on radiographic findings. Conversion to culture-negative sputum samples was achieved in 10 (24%) patients after CFZ-containing antibiotic treatment, and during treatment, there were significant decreases in the positivity of semiquantitative sputum cultures for acid-fast bacilli in both the initial (P = 0.018) and salvage (P = 0.001) treatment groups. Our study suggests that CFZ-containing regimens may improve treatment outcomes in patients with M. abscessus lung disease and that a prospective evaluation of CFZ in M. abscessus lung disease is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85019694371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019694371&partnerID=8YFLogxK

U2 - 10.1128/AAC.02052-16

DO - 10.1128/AAC.02052-16

M3 - Article

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

M1 - e02052-16

ER -